Please assess the completion status of the following clinical trial:

Trial Title: Black Widow Spider Antivenin for Patients With Systemic Latrodectism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Moderate to severe pain intensity measured using the visual analog scale (VAS score ≥ 40mm) at the start of screening phase (VAS 0)~* Diagnosis of latrodectism by the Investigator, with concurrence of diagnosis by a physician not directly involved with the study~* Moderate to severe pain intensity measured using the visual analog scale (VAS score ≥ 40mm) at Baseline (VAS 1)~Exclusion Criteria:~* Less than 10 years of age~* Presents to the emergency department of any healthcare facility greater than 24 hours after onset of symptoms~* Has a known (self-reported) hypersensitivity to fentanyl, morphine, diazepam, or equine serum~* History of significant cardiac, respiratory, hepatic or renal disease, psychiatric disorder or chronic pain syndrome that in the investigator's assessment would confound efficacy or safety endpoint assessment (e.g., a bite to the leg of a patient with reflex sympathetic dystrophy)~* History or suspected history or substance abuse~* Pregnant or breast-feeding~* Has a distracting injury with acute pain, or is unable to make a reliable self-report of pain intensity to pain relief based solely on the condition of interest~* Was already treated with Merck Antivenin Latrodectus Mactans for signs/symptoms related to the current widow spider bite~* Unable to provide a telephone number to be contacted for follow-up interviews on Days 2, 10, and 17 after discharge from the emergency department

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Analatro (Type: EXPERIMENTAL): Antivenin Latrodectus (Black Widow) Equine Immune F(ab)2
- Normal Saline Placebo (Type: PLACEBO_COMPARATOR): Normal Saline

Based on this trial design, predict the completion outcome and termination type (if applicable).